Are RNA insiders buying or selling?

In the last 90 days, Atrium (RNA) had 0 insider transactions. Track every executive trade, dollar amount, and date.

Which hedge funds own RNA?

133 hedge funds and asset managers hold RNA. Top holders: Trium Capital, Credit Industriel Et C, Y-Intercept (Hong Kong.

How much of RNA trades in dark pools?

0.099M RNA shares ($1M notional) traded off-exchange last week — block trades typical of institutional flow.

Atrium (RNA) — 61.2% Short — Squeeze Watch

$11.49

-0.08 (-0.69%)

Pre-Market: $12.55 (+1.06, +9.27%)

Weekly Expected Move ±5.9%

$10 $11 $11 $12 $13

NASDAQ · Healthcare · Biotechnology · Alpha Radar Strong Sell · Power 31 · $196.5M mcap · 16M float · 1.37% daily turnover · Short 58% of daily vol

Smart Money Score

Moderate 50

Insider—

Congress—

ETF Holdings—

Key Statistics

Market Cap$196.5M

52W Range11.38-16.77

Volume90,247

Avg Volume214,851

Beta0.19

Dividend—

Analyst Ratings

7 Buy 9 Hold 0 Sell

Consensus Hold

Company Info

CEOKathleen Gallagher

Employees511

SectorHealthcare

IndustryBiotechnology

IPO Date2026-02-27

Websiteatriumtherapeutics.com

10578 Science Center Drive
San Diego, CA 92121
US

619 876 0700

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

Latest News